Heron Therapeutics Inc vs Advanced Drainage Systems Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Advanced Drainage Systems Inc trades at $143.7 (market cap $10.68B). The key difference: Advanced Drainage Systems Inc is far larger — about 168.4× Heron Therapeutics Inc's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | WMS | |
|---|---|---|
Market Cap | $63.41M | $10.68B |
Sector | Health | Industrials |
52-Week High | $1.49 | $175.38 |
52-Week Low | $0.32 | $129.50 |
Enterprise Value | $161.31M | $12.29B |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Advanced Drainage Systems (WMS) trades at $143.95, down 3.03% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news highlights Q1 fiscal 2027 sales growth of 21% and consistent dividend payments, though cash flow turned negative in 2025 due to increased investing activity.
The outlook is mixed; analyst consensus is a Buy with a $185.86 price target, but near-term risks include volatile cash flows and high valuation multiples. Upside potential hinges on execution of growth initiatives and infrastructure demand, while margin pressure and economic sensitivity pose challenges.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →